Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Perol

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
World Journal of Urology|February 16, 2005
Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'ImmunothérapieSylvie Negrier, Frédéric Gomez, Jean-Yves Douillard, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|September 28, 2004
Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphomaChristelle Lenain, Charles Dumontet, Therese Gargi, et al.
Cancer|October 13, 2007
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trialSylvie Negrier, David Perol, Alain Ravaud, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2020
Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018)Paul Cottu, Bruno Coudert, David Perol, et al.
BMC Cancer|February 2, 2024
A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR)David Kryza, Armelle Vinceneux, Anne-Sophie Bidaux, et al.
EJNMMI Physics|January 20, 2017
3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcomaDavid Sarrut, Jean-Noël Badel, Adrien Halty, et al.
Anticancer Research|December 11, 2012
Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapyMarc Gigante, Guorong Li, Celine Ferlay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancerSylvie Négrier, David Perol, Alain Ravaud, et al.
Cancer|July 15, 2005
Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experienceValerie Mialou, Thierry Philip, Chantal Kalifa, et al.
Acta Oncologica (Stockholm, Sweden)|May 29, 2024
The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOSTLoic Verlingue, Marine Desevre, Marie Polito, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
World Journal of Urology|February 16, 2005
Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'ImmunothérapieSylvie Negrier, Frédéric Gomez, Jean-Yves Douillard, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|September 28, 2004
Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphomaChristelle Lenain, Charles Dumontet, Therese Gargi, et al.
Cancer|October 13, 2007
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trialSylvie Negrier, David Perol, Alain Ravaud, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2020
Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018)Paul Cottu, Bruno Coudert, David Perol, et al.
BMC Cancer|February 2, 2024
A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR)David Kryza, Armelle Vinceneux, Anne-Sophie Bidaux, et al.
EJNMMI Physics|January 20, 2017
3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcomaDavid Sarrut, Jean-Noël Badel, Adrien Halty, et al.
Anticancer Research|December 11, 2012
Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapyMarc Gigante, Guorong Li, Celine Ferlay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancerSylvie Négrier, David Perol, Alain Ravaud, et al.
Cancer|July 15, 2005
Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experienceValerie Mialou, Thierry Philip, Chantal Kalifa, et al.
Acta Oncologica (Stockholm, Sweden)|May 29, 2024
The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOSTLoic Verlingue, Marine Desevre, Marie Polito, et al.
Pageof 6